Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Variants in human CD48 lead to impaired T cell immunity and increased inflammation
Samantha Milanesi, Tiziana Lorenzini, Tommaso Marchetti, Diana Tintor, Raquel Planas, Ola Sabet, Lars Malmström, Sudip Acharya, Carson D. Williams, Zoe E. Manning, Jack H. Roser, Angelica C. Ehler, Michael Huber, Seraina Prader, Stefano Vavassori, Cullen M. Dutmer, Jordan K. Abbott, Jana Pachlopnik Schmid
Samantha Milanesi, Tiziana Lorenzini, Tommaso Marchetti, Diana Tintor, Raquel Planas, Ola Sabet, Lars Malmström, Sudip Acharya, Carson D. Williams, Zoe E. Manning, Jack H. Roser, Angelica C. Ehler, Michael Huber, Seraina Prader, Stefano Vavassori, Cullen M. Dutmer, Jordan K. Abbott, Jana Pachlopnik Schmid
View: Text | PDF
Research Article Immunology Inflammation

Variants in human CD48 lead to impaired T cell immunity and increased inflammation

  • Text
  • PDF
Abstract

CD48 is a surface molecule with immunoregulatory functions. Following our initial report of a patient with a de novo heterozygous variant at amino acid S220 in the CD48 gene, we describe a second, unrelated patient with similar features of immune dysregulation and a missense change affecting the same residue. To further elucidate the specific pathogenic mechanisms of the identified variants, we reviewed patient records, analyzed patient-derived cells, and employed complementary in vitro and in vivo model systems, including transfected cell lines and CD48-deficient mice. We demonstrate that the variants are associated with altered distribution of CD48, characterized by diminished CD48 surface expression, intracellular retention, and activation of ER stress signaling. Patient T cells displayed increased susceptibility to apoptosis, reduced antiviral responses, and enhanced inflammation. Both patients exhibited T cell lymphopenia, a restricted T cell receptor repertoire diversity, and oligoclonal expansions consistent with antigen-driven selection. In parallel, virally infected CD48-deficient mice recapitulate key aspects of the human phenotype, including delayed antiviral immune responses, impaired viral clearance, and pronounced inflammation. We conclude that identified variants compromise CD48 cell surface localization, impair T cell survival and function, and predispose to inflammation, thereby highlighting the role of CD48 in immune regulation and the prevention of excessive inflammation.

Authors

Samantha Milanesi, Tiziana Lorenzini, Tommaso Marchetti, Diana Tintor, Raquel Planas, Ola Sabet, Lars Malmström, Sudip Acharya, Carson D. Williams, Zoe E. Manning, Jack H. Roser, Angelica C. Ehler, Michael Huber, Seraina Prader, Stefano Vavassori, Cullen M. Dutmer, Jordan K. Abbott, Jana Pachlopnik Schmid

×

Figure 4

TCR repertoire abnormalities in patients with S220 CD48 variants.

Options: View larger image (or click on image) Download as PowerPoint
TCR repertoire abnormalities in patients with S220 CD48 variants.
(A) He...
(A) Heatmap showing diversity metrics in CD4+ and CD8+ T cells from P1, P2, and 2 age-matched HDs (HD1 and HD2). The first row has a white-to-red color scale ranging from low (white) to high (red) template numbers. The remaining rows have a blue-to-white color scale ranging from low (blue) to high (white) diversity. (B) Cytoscape network representation of the top 20 most abundant clones, showing relative cumulative frequency in CD4+ and CD8+ T cells from HD1 compared with P1 and CD8+ T cells from HD2 compared with P2. Each node represents a clone; node size reflects its relative frequency, and color indicates the predicted antigen specificity. An asterisk indicates multiple predicted specificities, with a representative specificity selected for display. (C–F) Stacked bar plot illustrating the frequency of putative viral-specific TCRs. Each bar represents a sample, each color indicates a specificity, and the height reflects the cumulative TCR frequency. Thick lines: SARS-CoV-2 structural proteins, EBV lytic antigens, and immunodominant antigens of Influenza A (A) and B (B) viruses; intermediate lines: SARS-CoV-2 nonstructural or accessory immunodominant proteins and EBV latent immunodominant antigens; thin lines: SARS-CoV-2 accessory proteins and EBV less immunodominant antigens. NS1, nonstructural protein 1; M, matrix protein 2; NP, nucleoprotein; PB1, protein PB1-F2; M1, matrix protein 1; UL29/28, protein UL29/28; pp50, DNA polymerase processivity factor; IE-2, 45 kDa immediate-early protein 2; IE-1, immediate early protein IE1; pp65, 65 kDa phosphoprotein. (G) Blood TTV copy number (assessed by RT-PCR assay) during inflammatory episodes (light orange) or remission (dark orange) in P1 and P2 (pink) compared with immunocompromised patients (IC; n = 31, white) and HDs (n = 31, gray) using 1-way ANOVA followed by Tukey’s multiple-comparison test. (H) Change in TTV copy number over time in blood from P1 during inflammatory episodes (orange) or remission (light blue).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts